CVS To Offer Only Gilead’s Hepatitis C Treatments
CVS Health, the second-largest pharmacy benefit manager in the U.S., on Monday announced that it would cover only Gilead Sciences' two hepatitis C treatments for its patients. CVS Health said effective Jan. 7 it would make Gilead's Harvoni and Sovaldi the only hepatitis C treatment options for its patients who receive drug coverage through the pharmacy's standard commercial drug formulary, Medicare Part D, Medicaid and plans sold through the Affordable Care Act's exchanges.
- "CVS To Cover Gilead Hepatitis C Treatment Over AbbVie Regimen" (Berkrot/Humer, Reuters, 1/5).
- "CVS Gives Preferred Status to Gilead's Hepatitis C Drugs" (Walker, Wall Street Journal, 1/5).